Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i), according to baseline estimated glomerular filtration rate (eGFR).
Research Design and Methods
We used data from 14,671 TECOS participants assigned double-blind to receive sitagliptin or placebo added to existing therapy, whilst aiming for glycemic...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Accepted manuscript
- American Diabetes Association Publisher's website
- Diabetes Care Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- American Diabetes Association
- Copyright date:
- © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record